Venetoclax - AbbVie/Genentech
Alternative Names: A-1195425.0; ABT 0199; ABT 199; GDC-0199; RG-7601; RO-5537382; Venclexta; VENCLYXTO; VenclyxtoLatest Information Update: 29 Oct 2025
At a glance
- Originator Abbott Laboratories; Genentech; Walter and Eliza Hall Institute of Medical Research
- Developer AbbVie; Celgene Corporation; Dana-Farber Cancer Institute; Emory University; Genentech; Janssen Research & Development; M. D. Anderson Cancer Center; Merck & Co; Nantes University Hospital; National Cancer Institute (USA); Nordic Lymphoma Group; Pharmacyclics; Roche; Syros Pharmaceuticals; University Health Network
- Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Piperazines; Pyrans; Pyridines; Pyrroles; Small molecules; Sulfonamides
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Yes - Diffuse large B cell lymphoma; Multiple myeloma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia
- Registered Acute myeloid leukaemia
- Phase III Mantle-cell lymphoma
- Phase II Breast cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
- Phase I/II Chronic myelomonocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer
- No development reported B-cell lymphoma; Blastic plasmacytoid dendritic cell neoplasm; Cancer; Haematological malignancies; Myelodysplastic syndromes; Non-small cell lung cancer; Small cell lung cancer; Systemic lupus erythematosus
Most Recent Events
- 08 Oct 2025 AbbVie completes a phase I trial (In volunteers) in USA (PO, Tablet) (NCT06742086)
- 28 Aug 2025 No recent reports of development identified for phase-I development in Haematological-malignancies(Combination therapy, Late-stage disease) in USA (PO, Tablet)
- 21 Aug 2025 AbbVie completes the phase III VIALE-C trial for Acute myeloid leukaemia (Combination therapy, First-line therapy) in Argentina, Australia, Belgium, Brazil, Canada, China, Czech Republic, France, Germany, Greece, Hungary, Ireland, Japan, Mexico, the New Zealand, Norway, Puerto Rico, Russia, South Africa, South Korea, Spain, Taiwan, the USA and the United Kingdom (PO) (NCT03069352) (EudraCT2016-003900-30)